Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.

Takeda is promoting U.S. chief Julie Kim to be its next CEO. AstraZeneca and Daiichi's Enhertu has won an FDA nod to expand into HER2-ultralow breast cancer. | Takeda is promoting U.S. chief Julie Kim ...

Julie Kim, currently Takeda’s U.S. head, will replace Weber in June 2026 and become one of the few female CEOs of a top drugmaker.

Takeda has announced the appointment of Julie Kim as successor to Christophe Weber, its current president, CEO and ...

Q3 2025 Earnings Call Transcript January 30, 2025 Christopher O’Reilly: [Foreign Language] Let me start, I’d like to remind ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) Q3 2025Management ViewChristophe Weber, CEO, announced his retirement ...

Julie Kim has been running Takeda’s US operations since 2022 and will assume the role of CEO in June next year, subject to shareholder approval.

TOKYO -- Japan's Takeda Pharmaceutical announced on Thursday that CEO Christophe Weber will step down in June 2026 and be succeeded by current U.S. business head Julie Kim, who would become the ...

Takeda Pharmaceutical's strong earnings, dividends, and strategic moves make it an appealing investment despite US policy uncertainties. Read my earnings analysis.

Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while ...